Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid s Q2 Revenues Grow 90 Percent on Strong Reagent Sales; Loss Stays Flat

NEW YORK, Aug. 5 (GenomeWeb News) - Cepheid yesterday reported a steep increase in revenues along with flat losses for the second quarter of 2005.

 

The company had $21.4 million in revenues, up 89 percent from last year's $11.3 million during the same quarter. Most of this increase resulted from sales of reagents and disposables, which increased almost fourfold.

 

Research and developments costs climbed to $4.5 million from 3.9 million during the year-ago period.

 

Cepheid reported a net loss of $3.6 million, or $.09 per share, similar to last year's $3.7 million, or $.09 per share, for the same quarter.

 

As of June 30, Cepheid had $18.4 million in cash and cash equivalents, and $34 million in marketable securities.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.